Common variable immunodefi ciency (CVID) is a condition characterized by loll' levels ofimmun oglobulin (Ig) G and either IgA or IgM in the pr esence of recurrent inf ections. This disorder is associated with an increased risk of malignancy. Mucosa-associated lymphoid tissue (MALT) lymphoma is a recently re cogni zed fo rm of non-Hodgkin 's lymphoma that is not of ten present in the head. MALT lymphoma in pa tients with CVID is rare, and until now, it has not been reported in a cranial location outside of the parotid gland. We report the cases of 2 patients who had CVID and cranial MALT lymph oma outside of the parotid gland, and we describe their successful treatment with chemotherapy.
Introduction
The prim ary immunodeficiencies co nsist of a gro up of disorder s that are ca used by abn orm alities of the immune system; the most co mmo n of these disorders involve the humoral system. One of these hum oral di sorders is common variable imm unodeficienc y (CVID) , which is characterized by a decrease in the level of total immu noglob ulin (lg) G in addition to a redu ction in the level of either IgA or Iglvl.!? Patient s with CVID invariabl y experi enc e recurrent or chro nic infec tions," and they have a 5-to 13fold higher risk of mal ign ancy; 7% of these ma lignanc ies are non-Hodgkin ' s lymphomas."
Muco sa-associated lymphoid tissue (MA LT) lymphomas co nstitute a rec ently describ ed subse t of low-grade B-cell non-H odgki n' s lymphom as that are char acterized in part by their extranoda l loc atio n in the marginal zo nes of lymphoi d tissue." !' MA LT lymphom as in the head are rar e; in fact, thei r inciden ce is not know n because they were not recognized until only relatively rece ntly.l-! ' For this reason , optima l treatment for patients with thi s malignancy has yet to be determined .
In 2002 , Cunning ham-Rundles et al we re the first to report the simultaneous occ urrence of both CVID and cra nial MA LT lymphom a, which they found in 2 patient s amo ng a larger series.':' Both exp erienced a rec urrence of their mal ignancy 2 years after initial treatm en t.
In thi s article, we rep ort 2 new case s of co ncomitant CVID and cranial M ALT lymphom a, and the only 2 rep orted cas es in whi ch the MALT lymph omas were found outside the parotid gland. Th e 2 pat ients were trea ted succ ess fully with d ifferent therapeutic mod alities, and bo th have remai ned in rem ission since the completion of thei r therapy mor e than 2 years ago .
Case reports
Patient 1. A 60-year-old white woman had been previously diagnosed with CVID , and she had been rec eiving intra venous immunog lob ulin (lV IG) therap y once a month for the previous 5 yea rs. Her infect ions we re limited to one or two sinus infec tio ns per year. However , after having an upper right mola r extrac ted, she experienced del ayed healin g. Eventuall y, swe lling at the ex trac tion site prog ressed to the hard palate and crossed the midline.
Biopsy analysis revealed that the patien t had a largecell lymphoma. Immun oh istochemical stains were consiste nt with a MA LT lymphoma. Subseq uent co mp uted tom ograph y (CT) revealed the tum or had extended into the ma xillary and ethmo id sinuses was treated with dexamethasone, doxorubicin, cyclophosphamide, and vinblastine . A reduction of the tumor mass was noted after the first dose of therapy , and the lesion resolved completely within I year. She has remained in remi ssion for more than 2 years.
Patient 2. A 53-year-old white woman with a diagno sis of CVID had been receiving IVIG therapy for several years. She experienced fewer infections after the initiation of IVIG therapy.
On routine physical examination, bilateral propto sis was noted . CT of the orbits demonstrated a mass effect behind the globes (figure 2). A biopsy of the mass revealed that it was a low-grade lymphoma, and the results of immunohistochemical staining were consistent with a MALT lymphoma. Magnetic resonance imaging demonstrated simil ar tissue in the mediastinum . The patient was treated with anti-CD20 antibody therap y, and a reduction in the mass was noted immediately. The tumor resolved completely within 4 weeks. Thi s patient has also remained in remission for more than 2 years.
Discussion
CVID is a primary immunodeficiency that affects the humor al arm of the immu ne system and interfere s with the proper pro-duction of immunoglobulins. It is characterized by a decrease in the serum IgG level in addition to a decrease in the serum level of either IgA or IgM. The number of circul ating B cell s in affected patient s may be reduced , but they respond to appropri ate in vitro stimulation with the production and secretion of immunoglobulin. After Tcell receptor stimulation, most patients also experience a decrea se in the production of interleukins, possibly because of a defect in the signal transduction system ofCD4 T cells .' In addition to abnormal immunoglobulin levels, a diagno sis of CVID is based on the presence of recurrent infections (usually affecting the sinopulmonary tract) and the excl usion of other know n causes of immunodefi-TC HEUR EKDJIAN, JENKINS , HOSTOFFER ciency.1-3 Patients with CVID have a higher incidence of autoimm une, gastrointestinal, and granulomatous disease and a significantly higher risk of malignancy.?"
Kinlen et al reported that patient s wit h CVID had a 5fold higher incidence of cancer, which was primarily a reflection of a 47-fold increase in the number of stomac h cancers and a 30-fold increa se in the number of Iymphornas.' Cunningham-Rundles et al found that the risk was even higher; they reported that men and women had an 8and 13-fold increase in malig nancy in general, respectively , and that women had a 438-fold higher risk of lymphoma." Th e rea sons for these higher risks are not clear, but two ca uses have been post ulated : (1) immune dysregulation, which alters the immune system's ability to identify and destroy malignant cells, and (2) repeated or chronic antige n stimulation , whic h may lead to abnormal immune system activation. IS According to the latter hypothesis, the hig her risk of lymphoma in CVID patients might be attributable to the chronic stimulation and proliferation of lymphocytes.i-"
MALT lymphomas are a recently recognized type of non-Hodgkin' s lymphoma. They are characterized by the presence of a heterogeneous pop ulation of malignant cells-including centrocyte-like cells, lym phocytes, and plasma cells-in the margi nal zones of extra nodal lymphoid tissue. Immun ophenotyping of these tumor cells reveals that they express surface immu noglobul ins and Bcell antigens but lack CD5, CD IO, and CD23 ,u MALT lymphomas can arise anywhere in the body, but initial presentation in a crani al site is extremely rare; as a result , the incide nce of cra nial MALT lymphomas is unknown . Therapeutic modalities have included local excision, radiation therapy, and chemotherapy, and responses have been genera lly favora ble.P:"
MALT lymph omas in patie nts with CVID are rare . Reichenberger et al reported a case of a pulmonary MALT lymph oma." One year later, Cunningham-Rundles et al reported a series of 5 patients with various MA LT lymphomas, 2 of whom had cranial tumors." Both of these tumors were in the parotid gland, a well -established location for cranial MA LT lymphomas. 12.13 One of these patients underwent excisional and rad iation therapy of the parotid tumor and experienced a number of extracranial recurrences beginn ing 2 years later; she was treated with repeat excision and chemothera py. The other patie nt underwent exc isio nal therapy witho ut radia tion and experienced an extracranial recurrence within 2 years ; she was then treated with chemotherapy.
The location of the MA LT lymphomas in our 2 patients was unusual; in fact , such a location has not been previously reported in patients with CVID. In addition, our 2 patients were ini tially treated with systemic therapy rather than loca l therapy, and both have been in remission for more than 2 years. Although immu nocompetent patients with cran ial MALT lymphomas have been successfully 354 treated with local therapy, immun ocompromised patients with CVID appear to exp erience better outcomes if they are treated initially with systemic therapy. These different outcomes may be the result of immune system dysregulation in patients with CV ID, which limits the body' s ability to identify, conta in, and destroy malignant cells and which can lead to an early metastasis of this usually low-grade malignancy.
In summ ary, this article is the first report of any CVID patients with cranial MALT lymphoma that did not involve the parotid gland. Our experience suggests that patients with CV ID and MALT lymphoma may experience a better outcome if they are initia lly treated with systemic therapy rat her than local therapy.
